Portal de investigación
ESTUDIO DE NUEVOS EJES DE QUIMIOCINAS COMO POTENCIALES DIANAS DE INTERVENCION EN LA OBESIDAD Y LA RESISTENCIA A LA INSULINA.
Datos básicos
Documentos
- No hay documentos
Participantes
Grupos y Plataformas de I+D+i
Financiadores - Promotores
INSTITUTO SALUD CARLOS III
INSTITUTO SALUD CARLOS III
Resultados del Ensayo Clínico
A novel pan-PPAR agonist (BP-2) normalizes metabolic and inflammatory parameters in vitro and in ob/ob mice
Meeting Abstract. 2023
CXCL16/CXCR6 axis arises as a potential peripheral biomarker of early COPD development - results from a pilot study
Marques P; (...); Sanz MJ
Article. 10.3389/fmed.2025.1636360. 2025
Key role of activated platelets in the enhanced adhesion of circulating leucocyte-platelet aggregates to the dysfunctional endothelium in early-stage COPD
Marques P; (...); Sanz MJ
Article. 10.3389/fimmu.2024.1441637. 2024
Machine Learning Model in Obesity to Predict Weight Loss One Year after Bariatric Surgery: A Pilot Study
Nadal, E; (...); Real, JT
Article. 10.3390/biomedicines12061175. 2024
Platelet hyperactivity as a trigger of platelet-leukocyte-endothelium interactions and subsequent cardiovascular complications in early-stage COPD
Marques, P; (...); Sanz, MJ
Meeting Abstract. 2023
The dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonism inhibits leukocyte adhesiveness to dysfunctional endothelium
Marques, P; (...); Piqueras, L
Meeting Abstract. 2023
